Self‐reported quality of life as a predictor of mortality in renal cell carcinoma

Cancer ◽  
2021 ◽  
Author(s):  
Ridwan Alam ◽  
Hiten D. Patel ◽  
Zhuo T. Su ◽  
Joseph G. Cheaib ◽  
Yasser Ged ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell

Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation

2010 ◽  
Vol 106 (11) ◽  
pp. 1643-1647 ◽  
Author(s):  
Hideaki Miyake ◽  
Toshifumi Kurahashi ◽  
Kazuki Yamanaka ◽  
Yutaka Kondo ◽  
Atsushi Takenaka ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Japanese Patients ◽  
Prospective Evaluation ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Retroperitoneoscopic Versus Open Surgical Radical Nephrectomy for Large Renal Cell Carcinoma in Clinical Stage cT2 or cT3a: Quality of Life, Pain and Reconvalescence

2006 ◽  
Vol 49 (2) ◽  
pp. 314-323 ◽  
Author(s):  
Wolfgang Dillenburg ◽  
Vassilis Poulakis ◽  
Konstantinos Skriapas ◽  
Rachelle de Vries ◽  
Nikolaos Ferakis ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Clinical Stage

scholarly journals Quality of Life in Patients With Metastatic Renal Cell Carcinoma: Assessment of Long-Term Survivors

2013 ◽  
Vol 11 (2) ◽  
pp. 149-154 ◽  
Author(s):  
Courtney Carmichael ◽  
Bertram E. Yuh ◽  
Virginia Sun ◽  
Clayton Lau ◽  
Joann Hsu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Long Term Survivors

scholarly journals Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial

2018 ◽  
Vol 36 (8) ◽  
pp. 757-764 ◽  
Author(s):  
David Cella ◽  
Bernard Escudier ◽  
Nizar M. Tannir ◽  
Thomas Powles ◽  
Frede Donskov ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Renal Cell Carcinoma ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Repeated Measures ◽  
Objective Response ◽  
Phase Iii ◽  
Advanced Renal Cell Carcinoma

Purpose In the phase III METEOR trial ( ClinicalTrials.gov identifier: NCT01865747), 658 previously treated patients with advanced renal cell carcinoma were randomly assigned 1:1 to receive cabozantinib or everolimus. The cabozantinib arm had improved progression-free survival, overall survival, and objective response rate compared with everolimus. Changes in quality of life (QoL), an exploratory end point, are reported here. Patients and Methods Patients completed the 19-item Functional Assessment of Cancer Therapy–Kidney Symptom Index (FKSI-19) and the five-level EuroQol (EQ-5D-5L) questionnaires at baseline and throughout the study. The nine-item FKSI–Disease-Related Symptoms (FKSI-DRS), a subset of FKSI-19, was also investigated. Data were summarized descriptively and by repeated-measures analysis (for which a clinically relevant difference was an effect size ≥ 0.3). Time to deterioration (TTD) was defined as the earlier of date of death, radiographic progressive disease, or ≥ 4-point decrease from baseline in FKSI-DRS. Results The QoL questionnaire completion rates remained ≥ 75% through week 48 in each arm. There was no difference over time for FKSI-19 Total, FKSI-DRS, or EQ-5D data between the cabozantinib and everolimus arms. Among the individual FKSI-19 items, cabozantinib was associated with worse diarrhea and nausea; everolimus was associated with worse shortness of breath. These differences are consistent with the adverse event profile of each drug. Cabozantinib improved TTD overall, with a marked improvement in patients with bone metastases at baseline. Conclusion In patients with advanced renal cell carcinoma, relative to everolimus, cabozantinib generally maintained QoL to a similar extent. Compared with everolimus, cabozantinib extended TTD overall and markedly improved TTD in patients with bone metastases.

Sign in / Sign up

Export Citation Format

Share Document